AUDIO-Medco eyes expansion in Europe to fuel long-term growth
With at least $60 billion in U.S. annual sales of brand name medicines going off patent between now and 2012 — Medco is in a sweet spot.
The question on investors’ minds? What will spur growth beyond the generic windfall five years out? CEO David Snow told the Reuters Health Summit expansion plans in Europe will be one of those drivers, and said talks are going on right now.